--Allakos Inc., a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced positive results from the single and multiple ascending Phase 1 study of ...

The company’s pipeline includes two first-in-class small molecule antagonists targeting MRGPRX2 for the treatment of various mast cell mediated disorders and MRGPRX4 for cholestatic pruritus.

Mast cell leukemia (MCL) is a quick-progressing condition that leads to the buildup of mast cells in your bone marrow and other tissues. Learn everything more about MCL and treatment options.

In preclinical studies, AK006 appears to provide deep mast cell inhibition and, in addition to its inhibitory activity, reduce mast cell numbers. For more information, please visit the Company’s ...

Moreover, mast cells release pro-inflammatory cytokines like interleukin (IL-)1, IL-6, and tumor necrosis factor (TNF). The breakdown of mast cell granules in the lungs may also worsen lung lesions.

Source: Maurer M, et al. Abstract L18. Presented at: AAAAI Annual Meeting; Feb. 23-26, 2023; Washington, D.C.